Iodine-131 Iobenguane (I-131 MIBG): A Radiopharmaceutical Powerhouse for Diagnosing and Treating Neuroendocrine Tumours

Iodine-131 iobenguane (I-131 MIBG) is a radiopharmaceutical agent that has gained significant attention in nuclear medicine due to diagnosing and treating neuroendocrine tumours.  These tumours, originating from the neural and endocrine systems, can cause various symptoms and complications.  Therefore, early diagnosis and targeted treatment are essential for successfully managing these malignancies.  This article will discuss the properties, mechanism of action, and applications of iodine-131 iobenguane in diagnosing and treating neuroendocrine tumours.

Iodine-131 iobenguane is a radiolabelled compound that comprises two essential components: iodine-131 (I-131), a radioactive isotope of iodine, and iobenguane, a guanethidine derivative that closely resembles the neurotransmitter norepinephrine.  The radiopharmaceutical agent works by exploiting the norepinephrine transporter system found on the cell membrane of neuroendocrine cells.  Due to its structural similarity to norepinephrine, iobenguane is selectively taken up by these cells via the norepinephrine transporter.

Once inside the tumour cells, the iodine-131 isotope emits beta particles, generating cytotoxic radiation. This radiation damages the cellular DNA and ultimately leads to cell death.  The emitted gamma radiation can be detected and imaged using gamma cameras, which enables the localisation and assessment of neuroendocrine tumours.

Iodine-131 MIBG Scintigraphy: A Superior Diagnostic Approach for Neuroendocrine Tumours

Iodine-131 iobenguane scintigraphy, or MIBG scintigraphy, is a valuable diagnostic tool for evaluating patients with suspected or confirmed neuroendocrine tumours.  The technique involves the intravenous administration of I-131 MIBG, followed by whole-body imaging using a gamma camera.  This allows for detecting primary tumours, metastases, and recurrent disease.  MIBG scintigraphy is particularly useful for assessing pheochromocytomas, paragangliomas, and neuroblastomas, among other neuroendocrine malignancies.

I-131 MIBG scintigraphy has several advantages over other imaging modalities, including its ability to detect small lesions and provide functional information about the tumour.  Additionally, it can help differentiate between benign and malignant lesions, as malignant neuroendocrine tumours typically demonstrate increased uptake of the radiopharmaceutical agent.  However, it is essential to consider that false-negative and false-positive results may occur, and other imaging techniques, such as CT or MRI, may be necessary for further evaluation.

Targeted Iodine-131 Iobenguane Therapy: A Promising Treatment for Inoperable and Metastatic Neuroendocrine Tumours

In addition to its diagnostic utility, iodine-131 iobenguane can be a targeted radionuclide therapy for patients with inoperable, metastatic, or recurrent neuroendocrine tumours.  The treatment, known as I-131 MIBG therapy, delivers high doses of radiation directly to the tumour cells while sparing surrounding healthy tissues.  This targeted approach can result in tumour shrinkage, symptom relief, and improved survival outcomes.

I-131 MIBG therapy is primarily utilised to treat malignant pheochromocytomas, paragangliomas, and neuroblastomas.  However, it may also be considered for other neuroendocrine tumours with demonstrated MIBG avidity.  The therapy is generally well-tolerated, with common side effects, including nausea, vomiting, and hematologic toxicity.  Therefore, monitoring patients during and after treatment for adverse events and assessing treatment response is crucial.


Iodine-131 iobenguane is a versatile radiopharmaceutical agent with significant diagnostic and therapeutic applications in managing neuroendocrine tumours.  Its ability to target tumour cells selectively while sparing healthy tissues makes it a valuable tool in identifying and treating these malignancies.  MIBG scintigraphy is a powerful diagnostic tool for detecting primary and metastatic lesions, while I-131 MIBG therapy offers targeted radionuclide treatment for patients with inoperable, metastatic, or recurrent disease.  While promising results have been achieved, it is essential to continue research on iodine-131 iobenguane to optimise its use and improve patient outcomes further.  The expanding role of nuclear medicine in oncology emphasises the importance of understanding and utilising agents like iodine-131 iobenguane to achieve the best possible outcomes for patients with neuroendocrine tumours.

Scroll to Top